Sohrab Kharabaf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sohrab Kharabaf has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Dao Le
Department of Medicine, University of California, Irvine, USA
3 shared publications- Ramy Hanna
Division of Nephrology, Department of Medicine, Hypertension and Kidney Transplantation, University of California, Irvine, Orange, USA
3 shared publications - Matthew Nguyen
Division of Nephrology, Department of Medicine, University of California Irvine, Irvine, California
2 shared publications - Arif Nihat Demirci
Department of Medicine, Division of Nephrology, Hypertension, and Renal Transplant, University of California, Irvine, USA
1 shared publication Caroline Gee
Department of Medicine, Division of Nephrology, Hypertension, and Renal Transplant, University of California, Irvine, USA
1 shared publication- Eric Frazier
University of California, Irvine, School of Medicine, California
1 shared publication
Latest Publications
- Open Access
- 3 March 2026
- Published by SAGE Publications in Clinical Medicine Insights: Case Reports
- Vol. 19
Immunoglobulin A Nephropathy With Associated Thrombotic Microangiopathy: Biopsy and Clinical Case Series
Introduction: IgA nephropathy (IgAN) with concurrent thrombotic microangiopathy (TMA) is an unusual combination of pathological findings that is associated with severe hypertension, proteinuria, and lower estimated glomerular filtration rate (eGFR). This series presents 7 patients with kidney biopsies demonstrating IgAN and concomitant TMA and presents a link by way of complement disorder. Case presentation: Seven patients all presented as IgAN with associated TMA coinciding with hypertension, proteinuria, and low eGFR. Six patients showed tubular atrophy or interstitial fibrosis and 5 of those 6 showed >50% of renal cortex containing tubular atrophy or interstitial fibrosis. Variations of low serum C3, high serum C4, elevated IgA or IgM proteins, and elevated CH50 were found in 6 of the 7 patients. Conclusions: Chronic changes seen like interstitial fibrosis and tubular atrophy appear to show a subacute or chronic nature of IgAN with TMA. The low serum C3, high C4, elevated CH50, suggests complement activation in endothelial and mesangial from IgG-IgA complexes known to occur in IgAN. This phenotype of IgAN with TMA may represent a more unique IgAN phenotype with a more severe clinical course and be indicative of underlying complement dysregulation.
- 3 March 2026
- Published by SAGE Publications in Clinical Medicine Insights: Case Reports
- Vol. 19
Open AccessImmunoglobulin A Nephropathy With Associated Thrombotic Microangiopathy: Biopsy and Clinical Case Series
Introduction: IgA nephropathy (IgAN) with concurrent thrombotic microangiopathy (TMA) is an unusual combination of pathological findings that is associated with severe hypertension, proteinuria, and lower estimated glomerular filtration rate (eGFR). This series presents 7 patients with kidney biopsies demonstrating IgAN and concomitant TMA and presents a link by way of complement disorder. Case presentation: Seven patients all presented as IgAN with associated TMA coinciding with hypertension, proteinuria, and low eGFR. Six patients showed tubular atrophy or interstitial fibrosis and 5 of those 6 showed >50% of renal cortex containing tubular atrophy or interstitial fibrosis. Variations of low serum C3, high serum C4, elevated IgA or IgM proteins, and elevated CH50 were found in 6 of the 7 patients. Conclusions: Chronic changes seen like interstitial fibrosis and tubular atrophy appear to show a subacute or chronic nature of IgAN with TMA. The low serum C3, high C4, elevated CH50, suggests complement activation in endothelial and mesangial from IgG-IgA complexes known to occur in IgAN. This phenotype of IgAN with TMA may represent a more unique IgAN phenotype with a more severe clinical course and be indicative of underlying complement dysregulation.
- Open Access
- 18 July 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report
Focal segmental glomerulosclerosis is a histopathological condition characterized by podocyte injury, which manifests as persistent proteinuria and progressive decline in renal function. It is classified into primary and secondary forms, with secondary focal segmental glomerulosclerosis often resulting from factors such as obesity, hypertension, or genetic mutations. The management of secondary focal segmental glomerulosclerosis remains challenging due to the lack of standardized therapeutic guidelines. This case report describes a 21-year-old male diagnosed with biopsy-proven secondary focal segmental glomerulosclerosis, likely due to obesity-related hyperfiltration, who exhibited significant improvement in proteinuria following cyclosporine therapy. Despite initial treatment with renin–angiotensin system inhibitors and prednisone, the patient continued to have persistent proteinuria. Low-dose cyclosporine therapy was introduced, leading to a marked reduction in proteinuria without deterioration in renal function. This case highlights the potential role of cyclosporine in the management of secondary focal segmental glomerulosclerosis, particularly in cases with suspected genetic predisposition. Further research is needed to determine the long-term efficacy and safety of cyclosporine in secondary focal segmental glomerulosclerosis management.
- 18 July 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Open AccessControlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report
Focal segmental glomerulosclerosis is a histopathological condition characterized by podocyte injury, which manifests as persistent proteinuria and progressive decline in renal function. It is classified into primary and secondary forms, with secondary focal segmental glomerulosclerosis often resulting from factors such as obesity, hypertension, or genetic mutations. The management of secondary focal segmental glomerulosclerosis remains challenging due to the lack of standardized therapeutic guidelines. This case report describes a 21-year-old male diagnosed with biopsy-proven secondary focal segmental glomerulosclerosis, likely due to obesity-related hyperfiltration, who exhibited significant improvement in proteinuria following cyclosporine therapy. Despite initial treatment with renin–angiotensin system inhibitors and prednisone, the patient continued to have persistent proteinuria. Low-dose cyclosporine therapy was introduced, leading to a marked reduction in proteinuria without deterioration in renal function. This case highlights the potential role of cyclosporine in the management of secondary focal segmental glomerulosclerosis, particularly in cases with suspected genetic predisposition. Further research is needed to determine the long-term efficacy and safety of cyclosporine in secondary focal segmental glomerulosclerosis management.
- Open Access
- 1 January 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Dasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report
Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase inhibitors. Dasatinib, a tyrosine kinase inhibitor used in managing chronic myeloid leukemia, has been linked to thrombotic microangiopathy. This report describes a 66-year-old female with chronic myeloid leukemia treated with dasatinib who developed renal-limited thrombotic microangiopathy. Progressive renal dysfunction found in the context of chronic kidney disease prompted extensive lab evaluation and evaluation, with a renal biopsy confirming thrombotic microangiopathy attributed to dasatinib-induced nephrotoxicity. Discontinuation of dasatinib led to a slight improvement in renal function; however, progressive decline necessitated dialysis. This case underscores the diagnostic and therapeutic challenges of dasatinib-induced thrombotic microangiopathy, emphasizing renal biopsy in diagnosis and monitoring. Individualized treatment strategies and further research should be conducted to optimize future outcomes.
- 1 January 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Open AccessDasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report
Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase inhibitors. Dasatinib, a tyrosine kinase inhibitor used in managing chronic myeloid leukemia, has been linked to thrombotic microangiopathy. This report describes a 66-year-old female with chronic myeloid leukemia treated with dasatinib who developed renal-limited thrombotic microangiopathy. Progressive renal dysfunction found in the context of chronic kidney disease prompted extensive lab evaluation and evaluation, with a renal biopsy confirming thrombotic microangiopathy attributed to dasatinib-induced nephrotoxicity. Discontinuation of dasatinib led to a slight improvement in renal function; however, progressive decline necessitated dialysis. This case underscores the diagnostic and therapeutic challenges of dasatinib-induced thrombotic microangiopathy, emphasizing renal biopsy in diagnosis and monitoring. Individualized treatment strategies and further research should be conducted to optimize future outcomes.